Glaukos Corporation · NYSE:GKOS

Glaukos — Investor Presentation (November 2025)

30 slides from Glaukos's investor presentation, November 2025

  1. Slide 1: Investor Presentation

    Slide 1: Investor Presentation

    Investor Presentation November 2025

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    Disclaimer All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. These statements are based on management’s current e

  3. Slide 3: We'll Go First: Core Growth Strategy

    Slide 3: We'll Go First: Core Growth Strategy

    WE’LL GO Leading-edge CORE GROWTH STRATEGY Dropless Commercial Innovation Therapies Excellence FIRST Pursuing big ideas that address clinical needs of large and/or underserved patient populations Challenging conventional paradigms to advance the standards of care and improve outcomes Building durabl

  4. Slide 4: Industry-Leading Innovation

    Slide 4: Industry-Leading Innovation

    Ocular Hypertension and INDUSTRY- Open-Angle Glaucoma LEADING INNOVATION 800 $ + Million Invested in R&D since 2018 AMD 14 DME RVO Disclosed pipeline Blepharitis Keratoconus Presbyopia programs in 2025 vs. Glaucoma 4 in 2015 Dry Eye © 2025 Glaukos Corporation 4

  5. Slide 5: 2025-26 Key Commercial Catalysts

    Slide 5: 2025-26 Key Commercial Catalysts

    2025-26 KEY COMMERCIAL Interventional CATALYSTS Glaucoma iDose® TR iStent infinite® Focused on establishing robust growth engines centered on proven, Keratoconus foundational therapies iLinko2n with EpioxaTM that improve the standard of care © 2025 Glaukos Corporation 5

  6. Slide 6: Disrupting the Status Quo

    Slide 6: Disrupting the Status Quo

    DISRUPTING DROPS = POOR PATIENT COMPLIANCE & REDUCED QUALITY OF LIFE 90 50 Topical meds remain the dominant glaucoma treatment but… Complex dosing regimens, instillation difficulties and THE STATUS % % chronic side effects are common problems > ~ QUO & of patients are non- of patients purposely disc

  7. Slide 7: IG: Led by iDose TR, Groundbreaking Innovation

    Slide 7: IG: Led by iDose TR, Groundbreaking Innovation

    IG: LED BY iDOSE TR, iDose TR is designed to provide 24/7, continuous, long-duration drug therapy to address ubiquitous patient non-compliance with topical GROUND- medications BREAKING <0.5mm INNOVATION 1.8mm Unique Drug Formulation 75 mcg of a novel, proprietary, preservative-free travoprost formul

  8. Slide 8: IG: A New Paradigm

    Slide 8: IG: A New Paradigm

    IG: A NEW PARADIGM The workhorse; foundational therapy in algorithms across the disease stage spectrum SLT Designed to provide 24/7 long-duration sustained release of travoprost directly into the anterior chamber; for full range of disease progression where goal is to reduce IOP OR DRUG DELIVERY OCU

  9. Slide 9: Driving IG Forward

    Slide 9: Driving IG Forward

    DRIVING IG Further broaden market access among MACs, FORWARD Methodical launch; continually commercial and Medicare Advantage (MA) payors Eight journal expanded trained surgeon pool articles published Accelerate marketing investments as Permanent universe of trained surgeons grows J-Code Cat III CPT

  10. Slide 10: IG & the Forever Patient

    Slide 10: IG & the Forever Patient

    IG & THE COMPREHENSIVE OPHTHALMOLOGY PRACTICE: CONVENTIONAL MODEL Optimizing referral network and Glaucoma care predominantly single Patients can be lost to follow-up and FOREVER practice administration for cataract and refractive care treatment per patient, then referred back to OD or glaucoma spec

  11. Slide 11: Strong IG Clinical Data

    Slide 11: Strong IG Clinical Data

    STRONG IG CLINICAL DATA iDose TR: Phase 3 data confirms long duration 81 % OF iDOSE TR SUBJECTS WELL-CONTROLLED ON THE % PATIENTS WELL CONTROLLED ON THE SAME OR FEWER SAME OR FEWER IOP-LOWERING TOPICAL MEDICATIONS TOPICAL IOP-LOWERING MEDS IN PHASE 3 TRIAL AT 3 YEARS3 % AT 12 MONTHS AT 36 MONTHS 70%

  12. Slide 12: Strong IG Safety Data

    Slide 12: Strong IG Safety Data

    STRONG IG iDose TR: Phase 3 & Phase 2b safety data SAFETY DATA Ph 3 Trials Ph 2b Trial Topical PGAs2 3 Years 3 Years No adverse events of periorbital fat Up to 70% incidence atrophy In controlled studies, the most common ocular Very low conjunctival hyperemia 30%-50% incidence adverse reactions in 2

  13. Slide 13: Power of Combined Therapy

    Slide 13: Power of Combined Therapy

    POWER OF ≥3 Meds NUMBER OF MEDICATIONS BY % OF PATIENTS (US)1 COMBINING THERAPIES COMBINED 24% 1 Med Combining multiple topical meds is widely used to Combinatorial therapy has potential to better control IOP with different mechanisms of action 48% THERAPY manage IOP by increasing 2 Meds outflow and

  14. Slide 14: Estimating the Domestic IG Opportunity

    Slide 14: Estimating the Domestic IG Opportunity

    ESTIMATING THE INTERVENTIONAL GLAUCOMA1 DOMESTIC IG MIGS + CATARACT 22M 13M 12M OPPORTUNITY 0.5M eyes eyes eyes eyes Annual Procedures Diagnosed & Diagnosed Treated Prevalence Are non-compliant and/or Have physical limitations intolerant with topical meds that impede their ability to use topical med

  15. Slide 15: IG Product Roadmap

    Slide 15: IG Product Roadmap

    IG PRODUCT PRODUCT PATIENT STATUS iStent / iStent inject / iStent Mild-to-Moderate Glaucoma with Cataract FDA Approved (2012, 2018, 2020) inject W ROADMAP iStent infinite Glaucoma (failed on prior therapy) FDA Cleared (2022) iStent infinite Glaucoma (label expansion) Active PMA Study / EU MDR Cert (

  16. Slide 16: IG: A Vision for the Next 10 Years

    Slide 16: IG: A Vision for the Next 10 Years

    IG: A VISION FOR THE NEXT 6 5 A new breed of IG specialist could emerge, conducting primarily injection therapy while vertically integrated ODs and 10 YEARS OD referral networks provide preparatory patient services 4 PE groups are likely to gravitate to IG therapy due to the significant clinical ben

  17. Slide 17: Advances in Corneal Health

    Slide 17: Advances in Corneal Health

    RARE DISEASE: Keratoconus is vastly underdiagnosed and untreated1 ADVANCES IN • Typical onset in teenage years, most aggressively CORNEAL advancing in patients under age 30 HEALTH • ~90% of cases are bilaterial • Can lead to loss of visual function and blindness if left untreated Keratoconus is a de

  18. Slide 18: Epioxa Approved by FDA

    Slide 18: Epioxa Approved by FDA

    RARE DISEASE: EPIOXA Groundbreaking advancement in keratoconus treatment, APPROVED BY ushers in a new standard-of-care FDA DESIGNED TO: Minimize pain Improve patient comfort Streamline procedure Increase recovery Transformative, incision-free, topical drug therapy without • Approval based on two Pha

  19. Slide 19: Epioxa Launch Planned for Q1 2026

    Slide 19: Epioxa Launch Planned for Q1 2026

    RARE DISEASE: EPIOXA LAUNCH Comprehensive set of programs focused on supporting patients and families across the treatment journey PLANNED FOR Q1 2026 awareness >>> diagnosis >>> treatment KEY INITIATIVES: Streamlined patient access support programs Substantial investments planned to increase patien

  20. Slide 20: Customized, Spherical Therapy

    Slide 20: Customized, Spherical Therapy

    WHAT IF? CUSTOMIZED, THIRD-GENERATION iLINK THERAPY DESIGNED TO: • Use biomechanical modeling to SPHERICAL deliver customized, patterned treatment that matches each THERAPY patient’s unique corneal topography • Use proprietary algorithm to precisely target UV energy for Third-generation iLink therap

  21. Slide 21: iLink / KC Product Roadmap

    Slide 21: iLink / KC Product Roadmap

    iLINK / KC PRODUCT ROADMAP PRODUCT PATIENT STATUS Photrexa (Epi-off) Keratoconus FDA Approved (2016) Epioxa (Epi-on) Keratoconus FDA Approved (2025) iLink 3rd Generation Keratoconus Phase 2 Robust pipeline is designed to expand and enhance patient care options with iVeena (IVMED-80) Keratoconus Phas

  22. Slide 22: iLution Platform Update

    Slide 22: iLution Platform Update

    iLUTION POTENTIAL BENEFITS OF EYELID DELIVERY VS PRESCRIPTION EYE DROPS • Easier administration • Fewer side effects PLATFORM • Faster onset of action • Better compliance UPDATE DEMODEX BLEPHARITIS iLUTION DEMODEX BLEPHARITIS PROGRAM • Affects an estimated 25 million1 people in the US Transdermal dr

  23. Slide 23: Retina XR Platform Update

    Slide 23: Retina XR Platform Update

    RETINA XR Conventional intravitreal 39 Monthly or bi-monthly anti-VEGF injections are standard PLATFORM of care for AMD, DME and RVO but studies show that injections impose tremendous % treatment burdens on patients UPDATE and contribute to lack of Are lost to follow- 28 compliance up within 2 years

  24. Slide 24: Building the Business in Stages

    Slide 24: Building the Business in Stages

    BUILDING THE BUSINESS IN BUILDING THE iStent & Other Surgical iDose iLink iLution Retina STAGES BUSINESS IN iStent/iStent inject* iStent inject W* iDose TR iLution TR iDose TREX Stage 1: iStent infinite STAGES iDose Gen 3 INTERVENTIONAL PreserFlo GLAUCOMA iAccess Radius 2012  Mitosol IOP Sensor Sta

  25. Slide 25: Glaucoma Among Industry's Most Formidable Portfolios

    Slide 25: Glaucoma Among Industry's Most Formidable Portfolios

    PRODUCT PATIENT STATUS AMONG iStent / iStent inject / iStent inject W iStent infinite Mild-to-Moderate Glaucoma with Cataract Glaucoma (failed on prior therapy) FDA Approved (2012, 2018, 2020) FDA Cleared (2022) INDUSTRY’S iStent infinite Glaucoma (label expansion) Active PMA Study / EU MDR Cert (20

  26. Slide 26: Key 2025 Pipeline Milestones

    Slide 26: Key 2025 Pipeline Milestones

    KEY 2025 PROGRAM PATIENT INTENDED CLINICAL BENEFIT 2025 MILESTONE TARGET GLAUCOMA Mild-to-Moderate PIPELINE MIGS therapy Advance enrollment in PMA pivotal trial Glaucoma iStent infinite EU regulatory approval and commercial Glaucoma MIGS therapy MILESTONES launch Advanced-Refractory PRESERFLO MicroS

  27. Slide 27: Building the Business: Key Highlights

    Slide 27: Building the Business: Key Highlights

    BUILDING THE BUSINESS IN 84 NET SALES1 GLOBAL INFRASTRUCTURE GROSS MARGIN2 17 (in millions) (3Q 2025) $492.5 KEY STAGES Countries with % $383 20%+ HIGHLIGHTS $315 10-year direct operations 300+ CAGR $283 Global commercial 2022 personnel 2023 2024 2025 SPECIALIZED MANUFACTURING SALES MIX HEALTHY BALA

  28. Slide 28: We'll Go First

    Slide 28: We'll Go First

    WE’LL GO FIRST Innovation is at the core of everything we do. At Glaukos, we push the limits of science and technology to solve unmet needs in chronic eye diseases. © 2025 Glaukos Corporation 28

  29. Slide 29: © 2025 Glaukos Corporation 29

    Slide 29: © 2025 Glaukos Corporation 29

    © 2025 Glaukos Corporation 29

  30. Slide 30: GAAP to Non-GAAP Reconciliation - 3Q 2025

    Slide 30: GAAP to Non-GAAP Reconciliation - 3Q 2025

    Appendix GAAP to Non-GAAP Reconciliation - 3Q 2025 (in thousands) 3Q 2025 GAAP Amort. of Dev Non-recurring 3Q 2025 Non-GAAP Gross Margin Tech Intangibles, Write-down of Gross Margin Dev IP, and Dist Certain Rights Inventory Net Sales $ 133,537 $ 133,537 COGS $ 28,831 $ (6,007) $ (1,303) $ 21,521 Gro

Source: Internet Archive copy of s206.q4cdn.com

More decks from Glaukos Corporation

All 68 Glaukos decks